SynthesisInternational ophthalmology2026
Ocular outcomes of amniotic membrane transplantation in acute and chronic Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review.
Synthesis in International ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeStevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) can cause devastating systemic injury and ocular surface destruction. This systematic review aims to synthesize current clinical evidence on ocular outcomes following amniotic membrane transplantation (AMT) in patients affected by SJS/TEN in the acute and chronic phases of disease and to provide clarity on the efficacy of standard and novel surgical techniques.
methodsWe performed a systematic literature search in PubMed, Embase, Cochrane, Scopus, and Web of Science using a standardized search strategy. Screening, data extraction, and risk of bias assessments were performed by two independent reviewers using recommendations from the Cochrane Handbook. Studies were categorized based on timing of AMT and surgical technique, and ocular outcomes were recorded with a narrative synthesis.
resultsA total of 54 included studies supported the use of AMT in ocular SJS/TEN. Acute AMT, ideally within 2 weeks of symptom onset, resulted in a best-corrected visual acuity (BCVA) of 20/50 or better in most patients and low rates of long-term ocular sequelae. AMT covering the entire ocular surface was associated with better reported outcomes than Prokera in the included studies, although direct comparative evidence was limited. Novel sutureless surgical techniques using symblepharon rings and glue appeared to reduce surgical risks while maintaining comparable reported patient outcomes. AMT applied in the chronic phase was associated with some symptomatic improvement.
conclusionsThe available evidence suggests that standard and sutureless AMT should be considered in the ophthalmic management of acute phase SJS/TEN patients to help prevent chronic ocular sequelae. Chronic phase AMT may have optimal clinical utility when used in conjunction with other grafts. However, these findings are based largely on observational studies with heterogenous methodologies, and higher-quality comparative studies are needed to confirm these findings.
Indexed as
Identifiers
42663738What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.